文献速递心律失常冠心病

房颤合并心梗或PCI后口服抗凝联合抗血小板治疗的趋势

Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
PubMed 文献 · Heart · 2017-11-01

该研究基于丹麦全国登记数据,纳入2011年8月至2016年9月间心梗和/或PCI后30天存活的心房颤动患者共2946例,分析非维生素K口服抗凝药(NOAC)或维生素K拮抗剂(VKA)联合抗血小板治疗的时间趋势。结果显示,NOAC联合抗血小板的使用比例从2011年的10%上升至2016年的52%,并在2016年超过VKA联合抗血小板的使用。

要点

  • 房颤患者心梗/PCI后出院30天内,66.8%使用VKA联合抗血小板,33.2%使用NOAC联合抗血小板。
  • NOAC联合抗血小板使用比例从2011年10%增至2016年52%,并在2016年超过VKA联合抗血小板。
  • 研究人群高危血栓风险(CHA2DS2-VASc高评分占95.5%)和高出血风险(HAS-BLED高评分占31.7%)比例较高。

核心结论

  • 2011至2016年间,房颤患者心梗/PCI后NOAC联合抗血小板的使用增加,并在2016年超过VKA联合抗血小板。

研究设计与样本

  • 基于丹麦全国登记数据的观察性研究,纳入2011年8月22日至2016年9月30日期间心梗和/或PCI后30天存活的心房颤动患者共2946例。

主要发现

  • 2946例患者中,1967例(66.8%)使用VKA联合抗血小板,979例(33.2%)使用NOAC联合抗血小板。
  • VKA联合方案中,VKA+阿司匹林477例,VKA+氯吡格雷439例,VKA+阿司匹林+氯吡格雷1051例。
  • NOAC联合方案中,NOAC+阿司匹林252例,NOAC+氯吡格雷218例,NOAC+阿司匹林+氯吡格雷509例。
  • 总体人群中位年龄76岁(IQR 69-82),男性1995例(67.7%),以心梗为纳入事件者1613例(54.8%)。
  • 高CHA2DS2-VASc评分患者占95.5%,高HAS-BLED评分患者占31.7%。

临床怎么用

  • 房颤患者心梗/PCI后联合抗栓治疗中,NOAC联合抗血小板的使用呈上升趋势,2016年已超过VKA联合抗血小板。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI). METHODS: Using Danish nationwide registries, all patients with AF who survived 30 days after discharge from MI and/or PCI between 22 August 2011 and 30 September 2016 were identified. RESULTS: A total of 2946 patients were included in the study population, of whom 1967 (66.8%) patients were treated with VKA in combination with antiplatelet(s) (VKA+aspirin n=477, VKA+clopidogrel n=439, VKA+aspirin+clopidogrel n=1051) and 979 (33.2%) patients were treated with NOAC in combination with antiplatelet(s) (NOAC+aspirin n=252, NOAC+clopidogrel n=218, NOAC+aspirin+clopidogrel n=509). The overall study population had a median age of 76 years [IQR: 69-82] and consisted of 1995 (67.7%) men. Patients with MI as inclusion event accounted for 1613 patients (54.8%). Patients with high CHA2DS2-VASc score(congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, history of stroke/transient ischemic attack/systemic thromboembolism (2 points), vascular disease, age 65-75 years, and female sex) accounted for 132 2814 (95.5%) of patients, and patients with high HAS-BLED score (hypertension, abnormal renal/liver function, history of stroke, history of bleeding, age >65 years, non-steroidal anti-inflammatory drug usages, or alcohol abuse, leaving out labile international normalized ratio (not available), and use of antiplatelets (exposure variable)) accounted for 934 (31.7%) of patients. There was an increase from 10% in 2011 to 52% in 2016 in the use of NOACs in combination with antiplatelet(s). CONCLUSION: From 2011 to 2016, the use of NOAC in combination with antiplatelet(s) increased in patients with AF following MI/PCI and exceeded the use of VKA in combination with antiplatelet(s) by 2016.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sindet-Pedersen C, Staerk L, Lamberts M, et al. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Heart. 2017. PMID: 29092916. doi:10.1136/heartjnl-2017-311976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。